Search alternatives:
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 481 - 500 results of 26,156 for search '(( 50 ((ppm decrease) OR (a decrease)) ) OR ( 5 ((ng decrease) OR (mean decrease)) ))', query time: 0.60s Refine Results
  1. 481
    Effect of the Hill coefficient on estimates of <i>ε</i><sub>max</sub> (left column) and IC<sub>50</sub> (right column) for the logistic model with drug applied to the growth rate <i>a</i> (top row) or the carrying capacity <i>b</i> (bottom row).

    Effect of the Hill coefficient on estimates of <i>ε</i><sub>max</sub> (left column) and IC<sub>50</sub> (right column) for the logistic model with drug applied to the growth rate <... by Hope Murphy (8843516)

    Published 2020
    Save to List
    Saved in:
  2. 482
    Partial correlation of <i>ε</i><sub>max</sub> (left column) and IC<sub>50</sub> (right column) estimates at 10 days and 20 days (first and second bar of each color, respectively) on parameters <i>a</i> and <i>b</i> of each model.

    Partial correlation of <i>ε</i><sub>max</sub> (left column) and IC<sub>50</sub> (right column) estimates at 10 days and 20 days (first and second bar of each color, respectively) o... by Hope Murphy (8843516)

    Published 2020
    Save to List
    Saved in:
  3. 483
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 484
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 485
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 486
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 487
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 488
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 489
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 490
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 491
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 492
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 493
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 494
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 495
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 496
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 497
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 498
    Longer polyQ sequences decrease the nuclear localization of AR in the absence of hormone.

    Longer polyQ sequences decrease the nuclear localization of AR in the absence of hormone. by Carlos M. Roggero (11909585)

    Published 2022
    Save to List
    Saved in:
  19. 499
    Titanate Nanosheets/Cellulose Composite Showing Improved Crystallinity and Decreased Water Wettability by Gamma-Irradiation

    Titanate Nanosheets/Cellulose Composite Showing Improved Crystallinity and Decreased Water Wettability by Gamma-Irradiation by Yaowaluk Tariwong (22630109)

    Published 2025
    Save to List
    Saved in:
  20. 500
    Means ratings for FFM traits at each age interval for the self and others with post hoc analyses for mean differences.

    Means ratings for FFM traits at each age interval for the self and others with post hoc analyses for mean differences. by Joanna Gutral (12101779)

    Published 2022
    Save to List
    Saved in:

Search Tools: